Every record, in the right category.

Synthetic peptide · Recovery

A synthetic 15-amino-acid research peptide with extensive preclinical claims but little interpretable human efficacy evidence.

Peptide analog · Weight & Metabolism

An investigational triple GIP, GLP-1, and glucagon receptor agonist in late-stage metabolic research.

Peptide analog · Growth Hormone

A growth hormone-releasing hormone analog with an FDA-approved use for a specific HIV-associated lipodystrophy population.

Mitochondrial-derived peptide · Longevity

A mitochondrial-derived signaling peptide studied mainly in cells, animals, and small human physiology experiments.

Peptide fragment · Recovery

A marketed name for a synthetic thymosin-beta-4-related fragment; product identity and evidence are often conflated with full-length thymosin beta-4.

Synthetic peptide · Growth Hormone

A synthetic ghrelin-receptor agonist studied as a growth hormone secretagogue, without an FDA-approved therapeutic product.

Peptide analog · Weight & Metabolism

A GLP-1 receptor agonist used in FDA-approved medicines with a large randomized human evidence base.

Peptide analog · Weight & Metabolism

A dual GIP and GLP-1 receptor agonist used in FDA-approved medicines for defined metabolic indications.

Peptide analog · Growth Hormone

A synthetic fragment of growth hormone-releasing hormone with historical clinical use and no current FDA-approved drug product.

Synthetic peptide · Longevity

A mitochondria-targeted peptide known as elamipretide; FDA accelerated approval is limited to a specific Barth syndrome indication.

Peptide analog · Growth Hormone

A long-acting growth hormone-releasing hormone analog studied in early human pharmacology research.

Peptide fragment · Immune / Inflammation

A tripeptide fragment derived from alpha-melanocyte-stimulating hormone and studied primarily in preclinical inflammation models.

Native peptide · Recovery

A naturally occurring copper-binding tripeptide studied in tissue remodeling, skin, and wound biology.

Synthetic peptide · Immune / Inflammation

A synthetic version of a thymic peptide investigated as an immune modulator and used clinically in some countries outside the United States.

Native peptide · Recovery

A naturally occurring actin-binding peptide studied in tissue repair and regenerative biology.

Native peptide · Immune / Inflammation

A human antimicrobial peptide involved in innate immune signaling and host defense.

Peptide fragment · Weight & Metabolism

A synthetic fragment of human growth hormone investigated for metabolic effects, with limited human evidence.

Synthetic peptide · Longevity

A synthetic tetrapeptide associated with aging research, supported mainly by limited and difficult-to-verify clinical literature.

Peptide analog · Cognition

A synthetic ACTH-derived peptide investigated for neurologic and cognitive effects, with limited generalizable human evidence.

Peptide analog · Cognition

A synthetic tuftsin analog studied for neurobehavioral effects, with a small and geographically concentrated evidence base.

Native peptide · Cognition

A small endogenous research peptide associated with sleep physiology, with uncertain therapeutic relevance.

Melanocortin receptor agonist · Sexual Health

A melanocortin receptor agonist; bremelanotide is FDA approved for one narrowly defined indication under the Vyleesi label.

Melanocortin receptor agonist · Other

An unapproved synthetic melanocortin analog promoted for tanning and sexual effects despite important safety uncertainty.

Native peptide · Other

An endogenous tripeptide involved in cellular redox chemistry; treatment claims require route- and formulation-specific evidence review.

Small-molecule research compound · Weight & Metabolism

A small-molecule NNMT inhibitor studied in preclinical models; it is not a peptide and a human evidence snapshot has not yet cleared review.

Small-molecule medication · Skin & Hair

A small-molecule medication represented separately from peptides; approval, evidence, and risk depend on the product, route, and use.

Endogenous coenzyme · Longevity

An endogenous coenzyme with central biochemical roles; those roles do not by themselves establish outcomes for injected or intranasal formulations.

Small-molecule medication · Sexual Health

A PDE5-inhibitor medication with approved product contexts; compounded and combination formulations require their own product-level review.

Small-molecule medication · Sexual Health

A PDE5-inhibitor medication represented as an ingredient-level record; it should not be treated as interchangeable with every compounded combination.

Methylxanthine stimulant · Other

A methylxanthine stimulant included here as a disclosed combination ingredient, not as a peptide or a standalone treatment recommendation.

Amino acid · Other

A non-protein amino acid included here as a disclosed combination ingredient; ingredient identity does not establish the combination's outcomes.

Route-specific formulation · Recovery

An oral formulation record kept separate from the BPC-157 scientific entity because route and formulation can change what evidence is relevant.

Route-specific formulation · Cognition

An intranasal formulation record kept separate from the Semax entity; route-specific evidence remains under editorial review.

Route-specific formulation · Cognition

An intranasal formulation record kept separate from the Selank entity; route-specific evidence remains under editorial review.

Combination · Growth Hormone

A two-ingredient combination record. Evidence for either component is not automatically evidence for the combined formulation.

Named blend · Recovery

A market-facing blend name preserved for discoverability. Its exact composition must be verified from the dispensed product before component evidence can be applied.

Named blend · Skin & Hair

A market-facing blend name preserved for discoverability. Its exact composition must be verified from the dispensed product before component evidence can be applied.

Named blend · Recovery

A market-facing blend name preserved for discoverability. Its exact composition must be verified from the dispensed product before component evidence can be applied.

Route-specific formulation · Skin & Hair

A topical formulation record kept separate from the GHK-Cu scientific entity so product- and route-specific evidence is not overgeneralized.

Compounded formulation · Weight & Metabolism

A compounded formulation record distinct from FDA-approved semaglutide products; approval and equivalence cannot be inherited from the active ingredient alone.

Compounded formulation · Weight & Metabolism

A compounded formulation record distinct from FDA-approved tirzepatide products; approval and equivalence cannot be inherited from the active ingredient alone.

Route-specific formulation · Growth Hormone

An injectable formulation record separated from the sermorelin entity; formulation-specific evidence and status remain under review.

Route-specific formulation · Growth Hormone

An orally disintegrating formulation record separated from injectable sermorelin because route-specific exposure and evidence cannot be assumed equivalent.

Compounded formulation · Longevity

An injectable NAD+ formulation record. Endogenous biochemical function is not treated as clinical evidence for this administration route.

Compounded formulation · Longevity

An intranasal NAD+ formulation record kept separate from injection and from the endogenous coenzyme record.

Compounded formulation · Other

An injectable formulation record kept separate from endogenous glutathione; biochemical role alone does not establish treatment outcomes.

Compounded formulation · Sexual Health

A dosing- and formulation-specific tadalafil record. It does not inherit every conclusion from approved product labels without product-level verification.

Combination · Sexual Health

A two-medication combination record. Evidence and safety information for each ingredient do not automatically validate the compounded combination.

Combination · Sexual Health

A three-ingredient combination record. Ingredient identity is explicit, while combination-specific evidence remains under editorial review.